← 返回专利悬崖列表






米拉贝隆
Tier B · 提前布局Mirabegron · 2029 年到期全部品种 →
安斯泰来制药集团
原研
2011
首批上市
2029
到期年(公开口径)
$1.54B ▲
峰值销售
化学药
类型
靶点:ADRB3
商品名:Myrbetriq、Betanis/Betmiga/Myrbetriq、贝坦利、Betmiga、Betanis
适应症(已批准):神经性膀胱功能障碍、膀胱过度活动症
各地区研发/上市状态
美国
批准上市
2012-06-28
欧盟
批准上市
2012-12-20
中国
批准上市
2017-09-29
日本
批准上市
2011-07-01
合成路线与中间体7 routes
原研路线 × 1优化路线(非专利)× 5工艺路线 × 1
路线按「原研路线 → 优化路线 / 工艺路线(非专利)」排序。每条路线附本站自绘的路线流程图(中间体 → 原料药)与中间体表(编号 / CAS / 英文名),可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染,未使用任何第三方路线图。
原研Route 1步骤 5 · 总收率 310mg

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-001 | 20780-53-4 | (R)-2-phenyloxirane |
| MIRA-002 | 29968-78-3 | 2-(4-nitrophenyl)ethan-1-amine hydrochloride |
| MIRA-003 | 223673-34-5 | (R)-2-((4-nitrophenethyl)amino)-1-phenylethan-1-ol |
| MIRA-004 | 223673-35-6 | tert-butyl (R)-(2-hydroxy-2-phenylethyl)(4-nitrophenethyl)carbamate |
| MIRA-005 | 223673-36-7 | tert-butyl (R)-(4-aminophenethyl)(2-hydroxy-2-phenylethyl)carbamate |
| MIRA-006 | 29676-71-9 | 2-(2-aminothiazol-4-yl)acetic acid |
| MIRA-007 | 1329485-55-3 | tert-butyl (R)-(4-(2-(2-aminothiazol-4-yl)acetamido)phenethyl)(2-hydroxy-2-phenylethyl)carbamate |
优化Route 3步骤 4 · 总收率 89.1 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-002 | 29968-78-3 | 2-(4-nitrophenyl)ethan-1-amine hydrochloride |
| MIRA-006 | 29676-71-9 | 2-(2-aminothiazol-4-yl)acetic acid |
| MIRA-008 | 611-71-2 | (R)-2-hydroxy-2-phenylacetic acid |
| MIRA-009 | 521284-19-5 | (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide |
| MIRA-010 | 521284-21-9 | (R)-2-((4-nitrophenethyl)amino)-1-phenylethan-1-ol hydrochloride |
| MIRA-011 | 521284-22-0 | (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol hydrochloride |
优化Route 4步骤 4 · 总收率 5 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-001 | 20780-53-4 | (R)-2-phenyloxirane |
| MIRA-002 | 29968-78-3 | 2-(4-nitrophenyl)ethan-1-amine hydrochloride |
| MIRA-006 | 29676-71-9 | 2-(2-aminothiazol-4-yl)acetic acid |
| MIRA-012 | 100-52-7在售 | benzaldehyde |
| MIRA-013 | 211635-75-5 | N-benzyl-2-(4-nitrophenyl)ethan-1-amine |
| MIRA-014 | 223673-46-9 | (R)-2-(benzyl(4-nitrophenethyl)amino)-1-phenylethan-1-ol |
| MIRA-015 | 391901-45-4 | (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol |
优化Route 5步骤 5 · 总收率 7.81 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-006 | 29676-71-9 | 2-(2-aminothiazol-4-yl)acetic acid |
| MIRA-015 | 391901-45-4 | (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol |
| MIRA-016 | 104-10-9 | 2-(4-aminophenyl)ethanol |
| MIRA-017 | 104060-23-3 | tert-butyl (4-(2-hydroxyethyl)phenyl)carbamate |
| MIRA-018 | 695171-91-6 | tert-butyl (4-(2-oxoethyl)phenyl)carbamate |
| MIRA-019 | 2549-14-6 | (R)-2-amino-1-phenylethanol |
| MIRA-020 | - | tert-butyl (R)-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)carbamate |
优化Route 6步骤 4 · 总收率 60 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-019 | 2549-14-6 | (R)-2-amino-1-phenylethanol |
| MIRA-021 | 66659-20-9 | 2-(2-aminothiazol-4-yl)acetic acid hydrochloride |
| MIRA-022 | 89336-46-9 | 2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetic acid |
| MIRA-023 | 211102-84-0 | 2-(2-(benzylamino)thiazol-4-yl)acetic acid |
| MIRA-024 | 887576-08-1 | 2-(2-((ethoxycarbonyl)amino)thiazol-4-yl)acetic acid |
| MIRA-025a | 26407-07-8 | 4-(2-bromoethyl)aniline hydrochloride |
| MIRA-025b | 52273-60-6 | 4-(2-chloroethyl)aniline hydrochloride |
| MIRA-026 | 1616489-60-1 | tert-butyl (4-(2-((4-(2-bromoethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-027 | 1616489-61-2 | 2-(2-(benzylamino)thiazol-4-yl)-N-(4-(2-bromoethyl)phenyl)acetamide |
| MIRA-028 | - | ethyl (4-(2-((4-(2-chloroethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-029 | 1616489-66-7 | tert-butyl (4-(2-((4-(2-chloroethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-030 | - | tert-butyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-031 | - | (R)-2-(2-(benzylamino)thiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide |
| MIRA-032 | - | ethyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
优化Route 7步骤 5 · 总收率 18.7 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-016 | 104-10-9 | 2-(4-aminophenyl)ethanol |
| MIRA-019 | 2549-14-6 | (R)-2-amino-1-phenylethanol |
| MIRA-021 | 66659-20-9 | 2-(2-aminothiazol-4-yl)acetic acid hydrochloride |
| MIRA-022 | 89336-46-9 | 2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetic acid |
| MIRA-030 | - | tert-butyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-033 | 381721-84-2 | 2-(2-(((benzyloxy)carbonyl)amino)thiazol-4-yl)acetic acid |
| MIRA-034 | 64220-26-4 | 2-(2-(tritylamino)thiazol-4-yl)acetic acid |
| MIRA-035 | 1447822-02-7 | tert-butyl (4-(2-((4-(2-hydroxyethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-036 | 1447822-04-9 | benzyl (4-(2-((4-(2-hydroxyethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-037 | 1447822-06-1 | N-(4-(2-hydroxyethyl)phenyl)-2-(2-(tritylamino)thiazol-4-yl)acetamide |
| MIRA-038 | 1447822-03-8 | tert-butyl (4-(2-oxo-2-((4-(2-oxoethyl)phenyl)amino)ethyl)thiazol-2-yl)carbamate |
| MIRA-039 | 1447822-05-0 | benzyl (4-(2-oxo-2-((4-(2-oxoethyl)phenyl)amino)ethyl)thiazol-2-yl)carbamate |
| MIRA-040 | 1447822-07-2 | N-(4-(2-oxoethyl)phenyl)-2-(2-(tritylamino)thiazol-4-yl)acetamide |
| MIRA-041 | - | benzyl (R)-(4-(2-((4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)amino)-2-oxoethyl)thiazol-2-yl)carbamate |
| MIRA-042 | - | (R)-2-(2-((l1-phosphanyl)amino)thiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide |
工艺Route 2步骤 4 · 总收率 14.24 kg

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| MIRA-002 | 29968-78-3 | 2-(4-nitrophenyl)ethan-1-amine hydrochloride |
| MIRA-006 | 29676-71-9 | 2-(2-aminothiazol-4-yl)acetic acid |
| MIRA-008 | 611-71-2 | (R)-2-hydroxy-2-phenylacetic acid |
| MIRA-009 | 521284-19-5 | (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide |
| MIRA-010 | 521284-21-9 | (R)-2-((4-nitrophenethyl)amino)-1-phenylethan-1-ol hydrochloride |
| MIRA-011 | 521284-22-0 | (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol hydrochloride |
常见问题(FAQ)
米拉贝隆的适应症有哪些?
已批准的适应症包括:神经性膀胱功能障碍、膀胱过度活动症。
米拉贝隆的专利什么时候到期?
按公开口径,米拉贝隆的专利到期年为 2029 年。
米拉贝隆有几条合成路线?
本站收录 7 条合成路线,最短路线 4 步、总收率 14.24 kg。每条路线的中间体均带登记编号与 CAS 号。
米拉贝隆的关键中间体在哪里可以采购?
米拉贝隆的多条路线中间体已挂接 CAS 档案,其中 1 个 CAS 已有优贝德(Unibest)供应网络在售报价,可在本页路线表中直接查看并询价。
如何获取米拉贝隆中间体的报价?
在本页选择目标中间体的 CAS 进入档案页,或在询价页直接提交需求;CAS 会自动带入供需撮合流程,由供应网络反馈报价。
数据来源:多源数据交叉核实(仅结构化字段) · 2026-09-24